HUMANA INC. v. ACTAVIS ELIZABETH, LLC et al
Case Number:
2:18-cv-03299
Court:
Nature of Suit:
Judge:
Firms
- Arnold & Porter
- Baker Botts
- Buchanan Ingersoll
- Clark Hill
- Competition Law Partners
- Curtis Mallet-Prevost
- Dechert LLP
- Foley & Lardner
- Fox Rothschild
- Hausfeld LLP
- Kasowitz Benson
- Kelley Drye
- Kenny Nachwalter
- Kirkland & Ellis
- K&L Gates
- Lowenstein Sandler
- Lowey Dannenberg
- McDermott Will & Emery
- Morgan Lewis
- Polsinelli PC
- Proskauer Rose
- Reed Smith
- Schneider Wallace
- Steptoe LLP
- Tarter Krinsky
- Troutman Pepper
- White & Case
- Williams & Connolly
- WilmerHale
- Wilson Sonsini
Companies
- Akorn Inc.
- Allergan PLC
- Amneal Pharmaceuticals Inc.
- Avet Pharmaceuticals Inc.
- Breckenridge Pharmaceutical Inc.
- Dr. Reddy's Laboratories Ltd.
- Endo International PLC
- Fougera Pharmaceuticals Inc.
- Glenmark Pharmaceuticals Ltd.
- Hi-Tech Pharmacal Co., Inc.
- Humana Inc.
- Impax Laboratories, Inc.
- Lannett Company, Inc
- Lupin Ltd.
- Novartis AG
- Par Pharmaceutical Cos. Inc.
- Perrigo Co. PLC
- Sandoz International GmbH
- Sun Pharmaceutical Industries Ltd.
- Taro Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Upsher-Smith Laboratories Inc.
- Viatris Inc.
- West-Ward Pharmaceutical Corp.
- Wockhardt USA LLC
- Zydus Pharmaceuticals Inc.
Sectors & Industries:
-
November 05, 2018
Humana Seeks Case's Inclusion In Generic Price-Fixing MDL
Humana on Friday asked the Pennsylvania federal court overseeing the sprawling multidistrict litigation over generic drug prices to formally incorporate its action into the MDL, saying its claims target many of the same drugs that the group of states and proposed classes of drug buyers are targeting.
-
August 06, 2018
Humana Hits Generic-Drug Makers With Price-Fixing Claims
Insurance giant Humana has slapped a host of generic-drug makers with a sprawling racketeering suit in Pennsylvania federal court alleging they conspired to hike prices on a range of everyday medications from muscle relaxers to antidepressants, resulting in "extraordinary" prices over a four-year period.